A monoclonal antibody treatment (brand name REGEN-COV) has been authorized for emergency use by the FDA for patients 12 years of age and older in two situations:
- Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in people who are at high risk of progression to severe COVID-19, including hospitalization or death.
- Prevention of COVID-19 in people who:
- are at high risk of progression to severe COVID-19, including hospitalization or death, AND
- are either not fully vaccinated or are not expected to mount an adequate immune response (for example, immunocompromised people) AND
- were exposed to someone infected with SARS-CoV-2 (the virus that causes COVID-19) as a close contact OR are at high risk of exposure to someone with SARS-CoV-2 infection in an institutional setting (for example, nursing homes and prisons)
If either of those situations apply to you, please see a healthcare provider for further information to see if you qualify for this monoclonal antibody treatment. This treatment is NOT authorized for use in patients who are already hospitalized and/or require oxygen therapy because of COVID-19.
Healthcare providers: see REGEN-COV fact sheet from Regeneron Pharmaceuticals here for more detailed information about authorized uses, limitations, dosage, and safety.
Note: The CDC recommends waiting at least 90 days after receiving monoclonal antibody COVID-19 treatment before getting a COVID-19 vaccine.